The present disclosure relates to compounds of Formula (P) or (II′-0): (Formulae (I′), (II′-0)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

The present disclosure relates to compounds of Formula (I), (II), or (II′): (I), (II), (II′), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

Provided are a novel compound, an electrolyte for a lithium secondary battery containing the same, and a lithium secondary battery containing the electrolyte for a lithium secondary battery according to the present invention. The electrolyte for a secondary battery according to the present invention may have significantly excellent high-temperature stability, low-temperature discharge capacity, and life cycle characteristics.

Provided are a novel compound, an electrolyte for a lithium secondary battery containing the same, and a lithium secondary battery containing the electrolyte for a lithium secondary battery according to the present invention. The electrolyte for a secondary battery according to the present invention may have significantly excellent high-temperature stability, low-temperature discharge capacity, and life cycle characteristics.

The present disclosure provides for novel fragrance molecules, namely a range of related fragrance molecules all containing a cyclic acetal or dioxepane sub-structure in combination with a carbonyl sub-structure and a phenyl sub-structure.

Specifically, several compounds of the formula:

##STR00001## Wherein: R=is or contains a phenyl group R1=is or contains a methyl, ethyl, propyl, or butyl group, including branched groups or groups with additional methyl, ethyl or propyl sub-structures R2=is or contains a cyclic acetal group or dioxepane R3=is or contains a carbonyl group, including a ketone, methanal, ethanal, propanal, or acetyl group

The present disclosure provides for novel fragrance molecules, namely a range of related fragrance molecules all containing a cyclic acetal or dioxepane sub-structure in combination with a carbonyl sub-structure and a phenyl sub-structure.

Specifically, several compounds of the formula:

##STR00001## Wherein: R=is or contains a phenyl group R1=is or contains a methyl, ethyl, propyl, or butyl group, including branched groups or groups with additional methyl, ethyl or propyl sub-structures R2=is or contains a cyclic acetal group or dioxepane R3=is or contains a carbonyl group, including a ketone, methanal, ethanal, propanal, or acetyl group

The present disclosure relates to compounds of Formula (P) or (II-0): (Formulae (I), (II-0)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions. ##STR00001##

The present invention is directed to novel organoleptic compounds, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a dental product, an oral hygiene product and a medicinal product comprising the step of incorporating an olfactory acceptable amount of such novel organoleptic compounds, and a process of improving, enhancing or modifying a fragrance composition through the addition of an olfactory acceptable amount of such novel organoleptic compounds.